Healthcare >> CEO Interviews >> December 14, 1998
RICHARD L. LOVE has served as President, Chief Executive Officer and a
Director of ILEX Oncology, Inc. since it began operations in 1994. He
has more than 34 years of industry experience, with more than 20 years
in the biosciences industry. Prior to forming ILEX, Mr. Love was Chief
Operating Officer of CTRC Research from 1991 to 1994. From 1983 through
1991, he served as CEO of Triton Biosciences, Inc., a subsidiary of
Shell Oil Company, and led the sale of Triton Biosciences Inc. to Berlex
Laboratories, Inc., a subsidiary of Schering, AG Triton developed two
drugs that were ultimately approved by the FDA ' Fludara (fludarabine
phosphate) and Betaseron (recombinant human beta interferon). Mr. Love
earned his BS and MS in Chemical Engineering from Virginia Polytechnic
Institute. Profile
Mr. Love: ILEX is a drug development company focused very tightly in the
area of oncology. We were spun off from the Cancer
